MedTrace Logo

Fibrinogen as a Surrogate for Global Haemostasis in Plasma Exchange

NCT02095821 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 2

Last updated 2020-04-20

No results posted yet for this study

Summary

Plasma exchange is a frequently used therapy in many antibody-mediated disorders, such as humoral rejection after kidney transplantation. Treatment frequency is adjusted to daily measured fibrinogen blood levels to prevent bleeding complications. However, data about the correlation of fibrinogen blood levels and function of the coagulation system during plasma exchange therapy is scarce. In the present study we examine blood fibrinogen levels and coagulation factors as well as thrombin clotting time in patients under plasma exchange therapy.

Conditions

  • Clotting Disorder Due to Plasma Exchange Therapy
  • Humoral Rejection After Kidney Transplantation

Sponsors & Collaborators

  • Hannover Medical School

    lead OTHER

Principal Investigators

  • Sascha David, MD · Medical School Hannover

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-02-28
Primary Completion
2019-10-31
Completion
2019-10-31

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02095821 on ClinicalTrials.gov